Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Redhill Biopharma Ltd RDHL

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

NDAQ:RDHL - Post Discussion

Redhill Biopharma Ltd > Ya want to know why Redhill sh price moved higher!!!!!!!
View:
Post by Iseneschal on Jan 25, 2024 9:13am

Ya want to know why Redhill sh price moved higher!!!!!!!

RedHill Biopharma Announces $8 Million Registered Direct Offering

2024-01-25 06:05 PT - News Release

Jan. 25, 2024

TEL AVIV, Israel and RALEIGH, N.C.Jan. 25, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 10,000,000 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, at a purchase price of $0.80 per ADS, in a registered direct offering.  In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 10,000,000 ADSs.  The warrants will have an exercise price of $1.00 per ADS, will be immediately exercisable upon issuance and have a term of fiveyears following the issuance date.  The closing of the offering is expected to occur on or about January 29, 2024, subject to the satisfaction of customary closing conditions


You've all been had.......again!!!!!
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities